Colorectal Cancer

Drug Name: Fruzaqla Active Ingredient: fruquintinib Indication: To treat refractory, metastatic colorectal cancer Approval Date: 11/8/2023 Company: Takeda Pharmaceuticals America, IncMore: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217564s000lbl.pdf

Tempus, a leader in artificial intelligence and precision medicine, today announced that the U.S. Food and Drug Administration (FDA) has approved the company’s first Premarket Approval (PMA) application for its…